This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.
Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.
Veeva Systems (VEEV) Offerings Adopted by SK Life Science
by Zacks Equity Research
Veeva Systems' (VEEV) Vault Validation Management is expected to aid SK Life Science to accelerate validation processes for increased inspection readiness.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand
by Zacks Equity Research
Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.
Masimo (MASI) Posts Preliminary Q4 Results, Issues FY24 View
by Zacks Equity Research
Masimo's (MASI) fourth-quarter 2023 results are likely to reflect the impacts of the robust adoption of hearable products.
Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand
by Zacks Equity Research
Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.
Intuitive Surgical (ISRG) Preliminary Q4 Revenues Improve Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter revenues reflect a strong demand in procedure volume as China recovers following the resurgence of COVID-19 in early 2023.
Integer Holdings (ITGR) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.
Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales
by Zacks Equity Research
PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.
Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.
DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand
by Zacks Equity Research
DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales
by Zacks Equity Research
Avanos' (AVNS) revenue growth in the fourth quarter is likely to have been dampened by lower HA pain relief injection product sales.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout
by Zacks Equity Research
Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
Microbot Medical (MBOT) Announces Positive GLP Study Results
by Zacks Equity Research
Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Ensign Group (ENSG) Rises 23% in 3 Months: More Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth, courtesy of an extensive treatment network, higher rental revenues and uninterrupted dividend hikes.
MMSI or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MMSI vs. WST: Which Stock Is the Better Value Option?
Why Merit Medical (MMSI) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.